At Cellis, we are at the forefront of cell-based oncology therapy, specializing in innovative solutions for the treatment of solid tumors.
We have developed a breakthrough platform technology called Macrophage Drug Conjugate (MDC), which leverages the revolutionary TRAIN mechanism. This biologic discovery enables the efficient and highly targeted delivery of active compounds directly into the cytoplasm of cancer cells, leading to cell death and tumor shrinkage. MDC also reshapes the tumor microenvironment, fostering immune resistance to cancer growth.
Our intellectual property is protected through PCT patent applications, with additional filings pending. As we prepare for first-in-human clinical trials in Q2 2025, we continue to push the boundaries of cancer treatment through integrated therapeutic and diagnostic solutions.
Company Details
Cellis Questions
Cellis's website is cellis.eu
Cellis's LinkedIn profile is https://ch.linkedin.com/company/cellis-ag
Cellis has
2 employees.
View email and phone details for 2
employees at Cellis.
Cellis's industry is
Biotechnology Research
Cellis's top competitors are
Nanogroup S.a.,
Vaxican,
Adamed Pharma,
Ryvu Therapeutics,
Explorna Therapeutics,
Poltreg S.a.,
Vigo Photonics,
Aronpharma,
Jjp Biologics,
Celon Pharma S.a..
Cellis's categories are Biotechnology Research
Cellis's founding year is 2016
